Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-β-D-arabinofuranosylcytosine, a new anticancer drug
SKM Koller-Lucae, H Schott… - Journal of Pharmacology …, 1997 - ASPET
The interactions of N 4 -octadecyl-1-β-d-arabinofuranosylcytosine (NOAC), a lipophilic
derivative of 1-β-d-arabinofuranosylcytosine (ara-C), were studiedin vitro with human blood …
derivative of 1-β-d-arabinofuranosylcytosine (ara-C), were studiedin vitro with human blood …
Metabolism of the new liposomal anticancer drug N4-octadecyl-1-β-D-arabinofuranosylcytosine in mice
SKM Koller-Lucae, MJF Suter, KM Rentsch… - Drug metabolism and …, 1999 - ASPET
Metabolism and excretion of the new antitumor drug N 4 -octadecyl-1-β-d-arabinofuranosylcytosine
(NOAC) was investigated in mice. Mice were injected iv with tritium-labeled …
(NOAC) was investigated in mice. Mice were injected iv with tritium-labeled …
Lipophilic arabinofuranosyl cytosine derivatives in liposomes
R Schwendener, H Schott - Methods in enzymology, 2005 - Elsevier
Highly lipophilic drugs can be used therapeutically only by the addition of possibly toxic
solubilizing agents or by development of complex pharmaceutical formulations. One way of …
solubilizing agents or by development of complex pharmaceutical formulations. One way of …
[PDF][PDF] New amphiphilic heterodinucleoside phosphate dimers of 5-fluorodeoxyuridine: anticancer activity and cellular pharmacology in human prostate tumour cells
RMC Cattaneo-Pangrazzi - 2000 - research-collection.ethz.ch
Prostatecanceris a leading cause of morbidity and mortality among men. Current therapies,
including treatment with 5-fluorodeoxyuridine (5-FdU), a chemotherapeuticagent frequently …
including treatment with 5-fluorodeoxyuridine (5-FdU), a chemotherapeuticagent frequently …